Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

§
Marginalia
Code · STATUTE-COMPILATIONS · FDA Reauthorization Act of 2017 · Sec. 505

Sec. 505. ADDITIONAL PROVISIONS ON DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC USE

901 words·~4 min read·/statute-compilations/comps-15234/sec-505

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 505 ADDITIONAL PROVISIONS ON DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC USE ###
(a)Informing internal review committee Section 505A(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a(f)) is amended by adding at the end the following: > > #### “(7) Informing Internal Review Committee > > The Secretary shall provide to the committee referred to in paragraph
(1)any response issued to an applicant or holder with respect to a proposed pediatric study request.” > . ###
(b)Action on submissions ####
(1)In general Section 505A(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a(d)) is amended— #####
(A)by redesignating paragraphs
(3)through
(5)as paragraphs
(4)through (6), respectively; and #####
(B)by inserting after paragraph
(2)the following: > > #### “(3) Action on Submissions > > The Secretary shall review and act upon a submission by a sponsor or holder of a proposed pediatric study request or a proposed amendment to a written request for pediatric studies within 120 calendar days of the submission.” > . ####
(2)Conforming amendments #####
(A)Federal food, drug, and cosmetic act Section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a), as amended by paragraph (1), is further amended by striking subsection “(d)(3)” each place it appears and inserting “(d)(4)”. #####
(B)Public health service act Paragraphs (2), (3), and
(4)of section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) are amended by striking “section 505A(d)(3)” each place it appears and inserting “section 505A(d)(4)”. ###
(c)Plan **[**[21 U.S.C. 355a note](/us/usc/t21/s355a)**]** The Secretary of Health and Human Services, acting through the internal review committee established under section 505C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355d) shall, not later than one year after the date of enactment of this Act, develop and implement a plan to achieve, when appropriate, earlier submission of pediatric studies under section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a) or section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)). Such plan shall include recommendations to achieve— ####
(1)earlier discussion of proposed pediatric study requests and written requests with sponsors, and if appropriate, discussion of such requests at the meeting required under section 505B(e)(2)(C) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(2)(C)), as amended by section 503(a); ####
(2)earlier issuance of written requests for a pediatric study under such section 505A, including for investigational new drugs prior to the submission of an application under section 505(b)(1) of such Act (21 U.S.C. 355(b)(1)); and ####
(3)shorter timelines, when appropriate, for the completion of studies pursuant to a written request under such section 505A or such section 351(m). ###
(d)Neonatology Expertise ####
(1)In general Section 6(d) of the Best Pharmaceuticals for Children Act (21 U.S.C. 393a(d)) is amended by striking “For the 5-year period beginning on the date of enactment of this subsection, at” and inserting “At”. ####
(2)Draft guidance **[**[21 U.S.C. 355a note](/us/usc/t21/s355a)**]** Not later than 2 years after the date of enactment of this Act, the Secretary shall issue draft guidance on clinical pharmacology considerations for neonatal studies for drugs and biological products. ###
(e)Submission of Assessments Section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(d)(1)) is amended by adding at the end the following: “The Secretary shall inform the Pediatric Advisory Committee of letters issued under this paragraph and responses to such letters.”. ###
(f)Internal Committee Section 505C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355d) is amended by inserting “or pediatric rare diseases” after “psychiatry”. ###
(g)Report on Labeling of Orphan Drugs ####
(1)In general Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services shall submit to the Committee on Health, Education, Labor and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available, including through posting on the internet website of the Food and Drug Administration, a report on the lack of information in the labeling of drugs for indications that have received an orphan designation under section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb) with respect to the use of such drugs pediatric populations. ####
(2)Contents The report described in paragraph
(1)shall include— #####
(A)a list of drugs for which— ######
(i)an indication was granted an orphan designation under section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb); ######
(ii)an application described under section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(a)(1)) for such indication was submitted to the Secretary of Health and Human Services on or after April 1, 1999; and ######
(iii)the labeling for such indication lacks important pediatric information, including information related to safety, dosing, and effectiveness; #####
(B)a description of the lack of information referred to in subparagraph (A)(iii) for each drug for an indication on such list; and #####
(C)Federal policy recommendations to improve the labeling of drugs for indications that have received an orphan designation under such section 526 with respect to the use of such drugs pediatric populations.” # TITLE VI REAUTHORIZATIONS AND IMPROVEMENTS RELATED TO DRUGS
Connectionstraces to 7
Citation graph
cites case law
Sec. 505
ADDITIONAL PROVISIONS ON DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC USE
U.S.C.§ 355a
U.S.C.§ 262
U.S.C.§ 355d
U.S.C.§ 355c
U.S.C.§ 355
U.S.C.§ 393a
U.S.C.§ 360bbb
Cites 7Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.